---
schema_version: "secwatch.filing_event.v1"
accession: "0001689548-24-000058"
form_type: "8-K"
ticker: "PRAX"
cik: "0001689548"
company_name: "Praxis Precision Medicines, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:26:39.850997+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Praxis Q1 net loss $39.6M; cash $451.2M, positive PRAX-628 data; Essential3 topline H2 2024

## Summary
- Net loss $39.6M in Q1 2024 vs $37.5M a year ago; R&D expense $27.0M, G&A $15.3M.
- Cash $451.2M at April 30, 2024, from two public offerings ($161.6M Jan, $215.8M Apr); runway into 2027.
- PRAX-628 Phase 2a PPR study: 100% response; 80% complete at 15mg, 100% at 45mg; focal onset seizure studies start H2 2024 and H1 2025.
- Ulixacaltamide Essential3 trial: >50K pre-screening forms, >7K referrals; topline H2 2024 to support NDA in 2025.
- PRAX-562 EMBOLD study in pediatric DEEs: randomization completed; topline results expected Q3 2024.

## SEC filing metadata
- accession: 0001689548-24-000058
- form_type: 8-K
- ticker: PRAX
- cik: 0001689548
- company_name: Praxis Precision Medicines, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/0001689548-24-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/prax-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689548-24-000058
- JSON: https://secwatch.observer/filing/0001689548-24-000058.json
- Plain text: https://secwatch.observer/filing/0001689548-24-000058.txt

## Key facts
- Earnings Releases
  Praxis Precision Medicines, Inc. reported the first quarter 2024 results: net income $39.6 million.
  - Period: the first quarter 2024
  - Net income: $39.6 million
  - Result: reported results
  source text: Praxis Precision Medicines, Inc. (the “Company”) announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1689548/000168954824000058/0001689548-24-000058-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.